Atrial Natriuretic Factor
In clinical developmentAlso known as A-type natriuretic peptide, ANH - atrial natriuretic hormone, ANP, ANP - atrial natriuretic peptide+10 more
A-type natriuretic peptide, ANH - atrial natriuretic hormone, ANP, ANP - atrial natriuretic peptide, Atrial natriuretic hormone, Atrial natriuretic peptide, Atrial natriuretic peptides, Atrial natriuretic polypeptide, Atriopeptin, Atriopeptins, Auriculin (peptide), Cardiodilatin, Cardionatrine, Natriuretic peptides, atrial.
Recent clinical, regulatory, research and industry developments relating to this drug.
Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- The Journal of clinical investigation1
- Hosoda K1
- Jougasaki M1
- Mukoyama M1
- Nakao K1
- Obata K1
- Ogawa Y1
- Saito Y1
- Shirakami G1
- Kyoto University School of Medicine1
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials